FDA is adjusting drug review strategies, showing openness to less data, while China surpasses the U.S. in drug research.
2 reports, 2 independent
Updated Jun 28
Gone quiet
- Reports
- 2
- Developments
- 3
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA is adjusting drug review strategies, showing openness to less data, while China surpasses the U.S. in drug research.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Innovent Biologics commercializes mazdutide for OPKO's license.Sub-event
- An experimental drug, sourced from China, is under FDA scrutiny after marketing claims of being 'the ultimate good' and subsequent warnings were issued.Sub-event
FDA shifts regulatory approach and China overtakes the U.S. in drug research.1 source
Keep exploring
The entities involved
-
Innovent Biologics
Chinese Biopharmaceutical Company
Nothing else this week.
- FDA
-
Eli Lilly and Company
American pharmaceutical company
Related events
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- The FDA operates under US law to evaluate international clinical data.
- The US administration rejected a proposed FDA-style central AI regulator while acknowledging the need to compete with China in the AI race.
- The Trump administration is leading to FDA job cuts, while Elon Musk spearheaded the Department of Government Efficiency, and China has surpassed the US in clinical trial volume.
- A study author is based in Johns Hopkins School of Medicine, and the research is connected to Baltimore, now involving the FDA for drug approval.
Coverage
Newest first; wire copies grouped- foxbusiness.com
- Pharma VoiceFDA invites more data from abroad — with a wary eye on China This story was originally published on PharmaVoice. To receive daily news and insights, subscribe to our free daily PharmaVoice newsletter